Gemini Therapeutics Announces Leadership Appointment

Jason Meyenburg Joins Gemini Therapeutics as CEO

Cambridge, Mass., September 13, 2019 – Gemini Therapeutics, a precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders, today announced the appointment of Jason Meyenburg, MBA, as Chief Executive Officer (CEO). Mr. Meyenburg will also join the company’s Board of Directors.

“We are thrilled to have Jason assume the helm of Gemini. His leadership experience, industry expertise and passion for driving much-needed therapeutic innovation will help Gemini to maximize the broad opportunities presented by our innovative precision therapeutics pipeline,” said Stephen Squinto, Ph.D., Director of the Board. “On behalf of the entire company, I want to welcome Jason. I look forward to collaborating with him, the management team and the board as we work together to redefine treatment of AMD through genetics.”

Gemini’s first-in-class therapeutic candidates are matched to molecular abnormalities found in patients with high-risk genetic profiles. The company’s pipeline includes monoclonal antibodies, recombinant proteins and AAV-mediated gene therapies.

“I am excited to be joining Gemini’s experienced leadership team at a pivotal point in the company’s journey.  As we prepare to submit our first IND, advancing therapeutic options for high-risk genetic patient populations of AMD remains our steadfast goal at Gemini.Building out our leadership team is a key component of that progress,” said Jason Meyenburg, Chief Executive Officer.

Mr. Meyenburg joins Gemini from Orchard Therapeutics, where he previously served as Chief Commercial Officer.During his tenure at Orchard, the company acquired and integrated the gene therapy portfolio from GlaxoSmithKline and launched an IPO in 2019.

Before Orchard, Mr. Meyenburg was Chief Commercial Officer of Vtesse Pharmaceuticals, a company developing a therapy for the rare disease Niemann-Pick C in collaboration with the NIH, and of Sucampo Pharmaceuticals through the acquisition of Vtesse. Before Vtesse and Sucampo, he spent 13 years at Alexion Pharmaceuticals in roles of increasing responsibility, including Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas.

Gemini Therapeutics

Gemini Therapeutics is a precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and linked ocular disorders that are matched to molecular abnormalities found in patients with high clinical unmet need. The company has generated a rich pipeline including recombinant proteins, monoclonal antibodies, and gene therapies. Gemini’s Ocular Disease Platform (CLARITY Natural History Study and Registry), which is designed to provide unprecedented insight into the role of genetic risk in common retinal diseases, entered the clinic in December 2018. Gemini was launched with funding from leading life science investors and powered by academic partnerships around the world.

For more information, visit www.GeminiTherapeutics.com.

Contacts:

Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
617-903-8783